Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
05 Mars 2024 - 10:30PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced that Gwenn M. Hansen, Ph.D., chief
scientific officer of Nurix, is invited as a featured speaker in
two sessions at the American Association for Cancer Research (AACR)
2024 Annual Meeting, which will be held from April 5-10, 2024, in
San Diego, CA.
Dr. Hansen’s presentation “NX-5948, a brain-penetrant BTK
degrader with clinical activity in B-cell malignancies including
CNS lymphoma” will be featured in the Major Symposium session:
Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and
Early Preclinical Advances that will be held from 10:15 -11:45 a.m.
PT on Tuesday, April 9, 2024.
Dr. Hansen is also a featured presenter in the Educational
session: Chemistry to the Clinic Part 1 of 3: Targeted Protein
Degraders: Delivering Degraders to the Site of Action that will be
held from 4:45 - 6:15 p.m. PT on Friday, April 5, 2024.
About NX-5948
NX-5948 is an investigational, orally bioavailable, small
molecule degrader of Bruton’s tyrosine kinase (BTK). NX-5948 is
currently being evaluated in a Phase 1 clinical trial in patients
with relapsed or refractory B cell malignancies. Nurix has
previously reported that NX-5948 is highly potent against a range
of tumor cell lines that are resistant to current BTK inhibitor
therapies, an important consideration in heavily pretreated CLL/SLL
patient populations. Additional information on the ongoing clinical
trial can be accessed at clinicaltrials.gov (NCT05131022).
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024